A Multicenter Prospective Smile Study investigate factors associated with the extent of symptoms and QOL improvement for First-Line Egfr-Tkis in Nsclc.

Trial Profile

A Multicenter Prospective Smile Study investigate factors associated with the extent of symptoms and QOL improvement for First-Line Egfr-Tkis in Nsclc.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Afatinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top